Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease

Transplantation Proceedings

Volumn 42, Issue 9 SUPPL., 2010, Pages

  Wuthrich R P ^a   Kistler, A D ^a   Serra, A L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LIVER WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 78649410115     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.008     Document Type: Article

References (17)

1. V.E. Torres, P.C. Harris, and Y. Pirson Autosomal dominant polycystic kidney disease Lancet 369 2007 1287
2. V.E. Torres, and P.C. Harris Autosomal dominant polycystic kidney disease: the last 3 years Kidney Int 76 2009 149
3. J.M. Shillingford, N.S. Murcia, and C.H. Larson The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease Proc Natl Acad Sci USA 103 2006 5466
4. R. Dere, P.D. Wilson, and R.N. Sandford Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR PLoS One 5 2010 e9239
5. Y. Tao, J. Kim, and R.W. Schrier Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease J Am Soc Nephrol 16 2005 46
6. P.R. Wahl, A.L. Serra, and M. Le Hir Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) Nephrol Dial Transplant 21 2006 598
7. M. Wu, P.R. Wahl, and M. Le Hir Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease Kidney Blood Press Res 30 2007 253
8. M. Wu, A. Arcaro, and Z. Varga Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease Am J Physiol Renal Physiol 297 2009 F1597
9. I. Zafar, F.A. Belibi, and Z. He Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD) Nephrol Dial Transplant 24 2009 2349
10. V.H. Gattone 2nd, R.M. Sinders, and T.A. Hornberger Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis Kidney Int 76 2009 178
11. J.M. Shillingford, K.B. Piontek, and G.G. Germino Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1 J Am Soc Nephrol 21 2010 489
12. Q. Qian, H. Du, and B.F. King Sirolimus reduces polycystic liver volume in ADPKD patients J Am Soc Nephrol 19 2008 631
13. R. Peces, C. Peces, and V. Prez-Dueas Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease NDT Plus 2 2009 133
14. A.R. Soliman, E. Ismail, and S. Zamil Sirolimus therapy for patients with adult polycystic kidney disease: a pilot study Transplant Proc 41 2009 3639
15. J.J. Grantham, V.E. Torres, and A.B. Chapman CRISP Investigators: Volume progression in polycystic kidney disease N Engl J Med 354 2006 2122
16. A.D. Kistler, D. Poster, and F. Krauer Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months Kidney Int 75 2009 235
17. A.L. Serra, A.D. Kistler, and D. Poster Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study BMC Nephrol 8 2007 13